This report provides an overview of the progress in the roll-out of COVID-19 vaccines in adults (aged 18 years and above) across EU/EEA Member States. It presents the number of vaccine doses distributed by manufacturers to each Member State for the different approved vaccines and the number of first..., second or unspecified doses administered to adult individuals overall, by age group and other selected target groups including healthcare workers (HCW) and residents in long-term care facilities (LTCF).
more
Social and behavior change (SBC) professionals have often been tasked to find ways to influence knowledge, attitudes, and practices, about vaccines. Now that the COVID-19 vaccines are becoming available worldwide, renewed emphasis and urgency for SBC efforts arise.
To that end, WHO has offered thre...e factors that play a role in vaccine hesitancy, the first two of which can be addressed by SBC: Complacency: Low perceived risk of vaccine-preventable diseases, and vaccination not deemed necessary. Other life/health issues are a greater priority.
Confidence: Low levels of trust in vaccines, in the delivery system, and in health authorities
Convenience: Barriers related to geographic accessibility, availability, affordability, and acceptability of services
This resource page provide a selection of SBC research, tools, and examples that aid in understanding this issue, especially in light of the recent availability of COVID-19 vaccines and the urgency for immunization worldwide.
more
How far apart should the doses of vaccines be? What if I miss my second dose? Can I get two doses from two different manufacturers? How was safety of vaccines ensured? WHO’s Chief Scientist, Dr Soumya Swaminathan explains in Science in 5.
A free course to help journalists translate the language of vaccine science and the promise of vaccine access into compelling human stories.
Extract from report of GACVS meeting of 29-30 November 2006, published in the WHO Weekly Epidemiological Record of 19 January 2007
Presentation OPT-SMC malaria vaccine workshop - Jan 2023
PAHO Revolving Fund Vaccine Prices for 2023
Vaksen Td
Sa Ou Bezwen Konnen
Early data from US biotech Moderna has revealed that its Covid-19 vaccine candidate is 94.5 per cent effective, raising hopes that a range of immunisations will be available to help end the pandemic.
The interim analysis of the vaccine, currently known as mRNA-1273, comes after 95 trial particip...ants contracted Covid-19, including just five who were given the coronavirus jab.
more
Vaksen DTaP (Difteri, Tetanòs, Koklich): Sa Ou Bezwen Konnen
The COVID-19 vaccine introduction toolbox equips all countries to prepare for and implement COVID-19 vaccination by providing guidance, tools, and training. This toolbox is intended to support Ministries of Health, health workers, partner organizations, and other stakeholders.
يحتاج العاملون الصحيون الذين يشاركون في نشر وتنفيذ التطعيم ضد كوفيد-19 إلى معرفة خاصة بكل لقاح لضمان تقديم اللقاحات بشكل آمن وفعال. يوفر هذا التدريب معلومات أساسية ح...ول لقاحات كوفيد-19 من خلال مقاطع فيديو تعليمية قصيرة، وشروح للقاحات، وتوجيهات عملية، ومعلومات حول موضوعات محددة، وعروض تقديمية قابلة للتنزيل. وهو يعتمد على دورة تدريب العاملين الصحيين على التطعيم ضدّ كوفيد-19 وتوجيه التخطيط الوطني لتوزيع اللقاحات والتطعيم ضد كوفيد-19. وهو يعتمد على دورة تدريب العاملين
more
Evaluation of COVID-19 vaccine effectiveness
17 March 2021
Vaksen Kont Epatit B
Sa Ou Dwe Konnen
Vaksen kont Varisèl (Saranpyon):Sa Ou Dwe Konnen